Publication: Prognostic significance of mucinous histology in metastatic colorectal cancer patients treated with regorafenib
Loading...
Files
Date
2023-01-01
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Objective: Prognostic factors for regorafenib therapy have not been fully defined. Mucinous adenocarcinoma (MAC) is a dis-tinct subtype of colorectal cancer (CRC). We investigated the significance of mucinous histology in patients treated with regorafenib for metastatic CRC (mCRC). Material and Methods: In this retrospective study, patients were stratified according to the presence of mucinous histology; >1% extracellular mucin was defined as mucinous component adenocarcinoma (MCAC), and containing no mucin was defined as non-MAC. The prognostic significance of mucinous histology for progression-free survival (PFS) and overall survival (OS) was evaluated by univariate and multivariate analyses. Results: A total of 103 patients were included, including 20 (19.4%) patients with MCAC and 83 (80.6%) patients with non-MAC. The median follow-up time was 8.6 months (range 1.8-31.6 months). The median PFS was lower in cases with MCAC than those with non-MAC (3.2 months vs. 3.6 months, respectively, p=0.01). Median OS was lower in MCAC patients than in non-MAC patients (4.3 months vs. 9.6 months, respectively, p=0.008). In multivariate analyses, mucinous histology was an independent risk factor [haz-ard ratio (HR): 2.2, p=0.003] for PFS and Eastern Cooperative Oncology Group-Performance Status (HR: 2.2, p=0.01), cancer antigen 19-9 (HR: 1.7, p=0.03), and mucinous histology (HR: 1.9, p=0.02) were independent risk factors for OS. Conclusion: This study revealed the prognostic value of mucinous histology in mCRC patients treated with regorafenib. Consideration of histologic features may be helpful in se-lecting patients for regorafenib therapy.
Description
Keywords
Tıp, Dahili Tıp Bilimleri, İç Hastalıkları, Onkoloji, Sağlık Bilimleri, Medicine, Internal Medicine Sciences, Internal Diseases, Oncology, Health Sciences, Klinik Tıp (MED), Klinik Tıp, ONKOLOJİ, Clinical Medicine (MED), CLINICAL MEDICINE, ONCOLOGY, colorectal neoplasms, Mucinous adenocarcinoma, prognosis, regorafenib, Mucinous adenocarcinoma, colorectal neoplasms, regorafenib, prognosis
Citation
ARIKAN R., Üstün H. S., Demircan N. C., Işik S., Telli T. A., Yaşar A., Çelebi A., Majidova N., Sever N., ÇELİKEL Ç., et al., "Prognostic Significance of Mucinous Histology in Metastatic Colorectal Cancer Patients Treated with Regorafenib", Journal of Oncological Science, cilt.9, sa.2, ss.53-61, 2023